Group 1 - On February 24, the first trading day after the Spring Festival, the A-share market experienced a rise, with all three major indices closing higher and over 4,000 stocks increasing in value, including 109 stocks hitting the daily limit [1] - Oil and gas stocks showed strong performance, with companies like Tongyuan Petroleum and Xinjing Power hitting the daily limit, while several others also saw significant gains [1] - The fertilizer and pesticide sector continued to strengthen in the afternoon, with multiple companies, including Liuguo Chemical and Yuntianhua, reaching the daily limit, driven by a rise in domestic urea prices [1] Group 2 - The electric equipment sector saw a strong performance, with multiple stocks hitting the daily limit, and reports indicated that many transformer factories are operating at full capacity, with some orders extending to 2027 [2] - Precious metals experienced a collective rise, with the sector increasing over 4%, and specific stocks like Xiaocheng Technology and Hunan Silver hitting the daily limit [2] - The main silver futures contract saw a significant increase of over 14%, with the price reported at 23,001 yuan per kilogram [3] Group 3 - The cultivated diamond concept stocks surged, with companies like Sifangda and Huanghe Xuanfeng hitting the daily limit, while the fiberglass sector remained active with International Composites achieving a historical high [5] - The software and cultural media sectors faced declines, with several companies, including Light Media and Wanda Film, hitting the daily limit downwards [5] - The Hong Kong stock market opened lower, with the Hang Seng Index dropping 1.81% and major tech stocks experiencing significant declines [5] Group 4 - Large model stocks performed well against the trend, with Zhiyu experiencing a rise of over 12%, and its market value briefly exceeding 300 billion HKD [6]

冼汉迪认为，香港的重点发展领域与广东省的整体发展战略高度契合。基于此，双方可以形成高效的协 作模式：在香港完成"从0到1"的研发突破，再到广东实现"从1到10"的产业化落地。 作为港区人大代表，冼汉迪一直致力于推动在人流、物流、资金流、信息流等方面实现更多突破。他希 望能让粤港融合的步伐再加快，同时也让香港更好地融入国家发展大局，因地制宜发展新质生产力。 今年是广东连续第四年召开全省高质量发展大会，进一步释放出广东坚定不移推动高质量发展的强烈信 号。本次大会围绕"制造业与服务业协同发展"的主题，广邀政企学研各界精英共商大计，旨在以敢为人 先的魄力，在"十四五"收官与"十五五"谋划的关键交汇期，跑出高质量发展的加速度，用关键之年的担 当作为，谱写现代化建设新篇章。 冼汉迪认为，广东省制造业和服务业双轮驱动取得的亮眼成绩，是高质量发展的核心竞争优势。 谈及粤港澳大湾区的协同发展，冼汉迪表示，粤港融合的程度正在持续加深。在过去一段时间里，香港 在基础研究领域已打下坚实基础，与广东省的联动也愈发紧密。"大家能看到，香港的新田科技城，包 括还有河套地区的建设进展非常快，这也是香港离广东省最近的区域。" 南方财经 21世 ...

Core Viewpoint - Guangdong leverages the advantages of the Greater Bay Area to promote supply chain integration, technological innovation, and talent cultivation, successfully incubating numerous startups and creating a closed loop from C-end consumer innovation to B-end industrial chain upgrades [1] Group 1 - By the end of 2025, the sales revenue of incubated enterprises is expected to see significant growth [1] - Multiple teams are emerging on the international stage, setting a model for national technological innovation and economic development [1]

0:00 南方财经 21世纪经济报道记者吴斌 上海报道 在纳指连续三年狂飙超20%后，美股科技股的涨势已经出现疲软迹象。 瑞士百达资产管理首席策略师卢伯乐（Luca Paolini）近日在接受21世纪经济报道记者独家专访时表 示，他并不看空科技股，但最好的日子可能已经过去了。对美股来说，最大的上行空间更有可能是小盘 股，而不是科技股。 在去年10月之前，几乎所有与人工智能相关的科技股都在上涨，虽然速度不一样，但方向都是一样的。 曾经有一段时间，人工智能交易推动着一切，投资者会购买任何与人工智能相关的企业，而不管它们在 做什么。 但如今市场正在变得更加挑剔。卢伯乐提醒，芯片制造商蓬勃发展，与谷歌相关的人工智能股票表现良 好，而与OpenAI相关的股票则略有挣扎，现在市场似乎在试图挑选赢家和输家。这意味着，一篮子人 工智能股票的表现将不如以前好，投资者将看到更少的收益。投资者的关注点正在从"增长多少"转 向"如何实现增长"。 展望未来，"中国科技公司在人工智能周期中处于有利地位。"卢伯乐强调，中国科技公司使用的商业模 式与美国同行不同，开放权重模型和巨大的国内市场将给中国公司带来很多好处，当前中国科技股的有 利环 ...

Core Viewpoint - Frontier Biotech has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small nucleic acid (siRNA) pipeline products, which is expected to improve the company's cash flow and support its R&D and platform upgrades, marking a significant development point amid ongoing losses since its IPO in 2020 [1][4][6]. Company Overview - Frontier Biotech was established in January 2013 and launched its first commercial product, Aikening® (Abavacavir), in June 2018, becoming the first original anti-AIDS drug in China [4]. - The company went public on the Shanghai Stock Exchange's STAR Market in October 2020, with an initial share price of 20.5 yuan, but has since experienced a downward trend in stock performance [4]. - Despite a 59.75% increase in sales volume of Aikening® in 2021, revenue declined by 13.13% to 40.50 million yuan due to price reductions, resulting in a net loss of 260 million yuan [4][6]. Financial Aspects - The licensing agreement with GSK includes an upfront payment of $40 million and a milestone payment of $13 million, with potential total payments reaching up to $950 million based on successful development and commercialization milestones [1][6]. - Frontier Biotech's revenue is primarily derived from Aikening®, with a projected revenue of 140 to 145 million yuan in 2025, representing a year-on-year growth of 8.13% to 11.99%, but with expected net losses widening to between 255 million and 290 million yuan [6]. R&D and Pipeline Development - The company is advancing multiple clinical development projects, including FB2001 for COVID-19 and FB3001 for musculoskeletal pain, although most pipeline products are still in early to phase II clinical stages [5][6]. - The small nucleic acid technology platform is a key focus for Frontier Biotech, with ongoing development in areas such as IgA nephropathy and dyslipidemia [5][6]. Industry Trends - The global small nucleic acid market is projected to grow significantly, reaching $39.2 billion by 2029, with increasing commercialization of siRNA drugs [7][8]. - Major pharmaceutical companies are actively investing in small nucleic acid technologies, with significant transactions occurring in the sector, indicating a competitive landscape [8][10]. - Chinese pharmaceutical companies are also making strides in the small nucleic acid space, with collaborations and acquisitions aimed at internationalizing their technologies [8][10].

Core Viewpoint - Frontier Biotech has entered into a significant exclusive licensing agreement with GlaxoSmithKline (GSK) for two small nucleic acid (siRNA) pipeline products, which is expected to enhance the company's cash flow and support its research and development efforts amid ongoing losses since its IPO in 2020 [1][8]. Company Summary - Frontier Biotech announced an exclusive licensing agreement with GSK on February 23, granting GSK global rights for the development, production, and commercialization of two siRNA products [1]. - The agreement includes an upfront payment of $40 million and a milestone payment of $13 million, with potential total payments reaching up to $950 million based on successful development and commercialization milestones [1]. - The company has been facing financial challenges, with a reported net loss of 260 million yuan in 2021, despite a 59.75% increase in sales volume of its core product, Aikening [6][8]. - Frontier Biotech's revenue primarily comes from Aikening and other products, with a projected revenue of 140 to 145 million yuan in 2025, indicating a year-on-year growth of 8.13% to 11.99% [8]. Industry Summary - The global small nucleic acid market is expected to grow significantly, projected to reach $39.2 billion by 2029, indicating a vast growth potential in this therapeutic area [8]. - As of December 2025, there are 29 small nucleic acid drugs on the market, with notable sales performance from Novartis's siRNA drug Leqvio, which reported sales of $1.198 billion in 2025, a 57% increase [9]. - The small nucleic acid sector is experiencing increased transaction activity, with potential total transaction values in the field expected to reach $36.5 billion by 2025 [9]. - Chinese pharmaceutical companies are actively engaging in international collaborations and mergers to enhance their presence in the small nucleic acid space, with significant partnerships and acquisitions reported [10][11]. - The industry is facing challenges, including a gap in the number of products developed by Chinese teams compared to global counterparts, particularly in late-stage clinical trials [12].

Group 1 - The A-share market indices opened significantly higher, with the securities sector showing slight activity, as evidenced by the CSI Securities Company Index rising by 0.02% [1] - The Securities ETF (159841) recorded a trading volume exceeding 120 million yuan, with a real-time premium rate of 0.13%, and saw a net subscription of over 50 million units during the trading session [1] - The Securities ETF has experienced a net inflow of 59.09 million yuan on the previous trading day (February 13), marking two consecutive days of net inflows, totaling 117 million yuan [1] Group 2 - In 2023, securities firms have completed bond issuance totaling 426.04 billion yuan, representing a substantial year-on-year increase of 243.97% [2] - The approved bond issuance quota for the year has reached 322 billion yuan, creating a significant capital raising environment, with several small and medium-sized securities firms entering the hundred billion yuan bond approval category [2] - The transformation of the securities industry is expected to bring new business growth points, benefiting from market recovery and favorable policy environments across brokerage, investment banking, and capital intermediary services [2]

Core Insights - The company focuses on providing services to farmers, aiming to enhance their productivity and connection to the land [1] Group 1 - The company emphasizes its role in supporting farmers, which is crucial for agricultural development [1] - The services offered are designed to help farmers optimize their operations and improve their yield [1] - The company's mission aligns with the broader goal of sustainable agricultural practices [1]

Core Viewpoint - The stock of Huagong Technology (000988.SZ), a leading optical module manufacturer, surged to its daily limit on February 24, reaching a price of 82.42 CNY per share and a market capitalization of 829 billion CNY, driven by strong demand and a full order book for its optical modules [1][4]. Company Performance - Huagong Technology reported a revenue of 110.38 billion CNY for the first three quarters of 2025, marking a year-on-year increase of 22.62%, and a net profit of 13.21 billion CNY, up 40.92% year-on-year [4]. - However, the company experienced a revenue decline of 10.33% year-on-year in the third quarter of 2025, attributed to fluctuations in its traditional business segments, while the optical module business continued to grow [5]. Industry Context - The strong order backlog for Huagong Technology reflects a broader trend in the global AI infrastructure market, with major companies like Google and Meta increasing their AI capital expenditures [5]. - The optical module market is expected to remain a mainstream solution for data center optical interconnections in the next two to three years, driven by high demand in AI applications [5].

Group 1 - Guangdong has regained its position as the top box office region in China, surpassing Jiangsu for the first time in five years during the Spring Festival period [1] - The average ticket price in Guangdong during the Spring Festival was 45.92 yuan, lower than most provinces in the country, emphasizing a "people-friendly" and "inclusive" approach [1] - The "movie+" strategy in Guangdong has integrated cinema with local businesses, allowing movie tickets to serve as discounts for dining and tourism, thus revitalizing commercial districts [1] Group 2 - The success of local films like "Night King" and animated feature "Boonie Bears: The Big Shrink" demonstrates the rising strength of Guangdong's film industry and its cultural resonance with local audiences [2] - The box office performance of "Boonie Bears: The Big Shrink" exceeded 690 million yuan, while "The Hidden Killer" surpassed 500 million yuan, indicating a growing demand for locally produced content [2] - The cultural connection between Guangdong, Hong Kong, and Macau is highlighted, showcasing how a single movie ticket can bridge cultural experiences across the Greater Bay Area [2]